Anti-VEGF in Real-world

Wenbin Wei

Status: Unknown

Conditions: Choroidal Neovascular Membrane; Non-proliferative Diabetic Retinopathy; Diabetic Macular Edema; Neovascular Age-related Macular Edema; Proliferative Diabetic Retinopathy; Retinal Vein Occlusion

Treatments: Drug: Ranibizumab; Drug: Conbercept; Drug: Aflibercept

Study type: Observational

Funder types: Other

Identifiers

NCT05222633

Anti-VEGF in real-world

Details and patient eligibility

About

Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-vascular endothelial growth factor therapy drugs. In the current study, the primary aim is to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.

Full description

Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases, including neovascular age-related macular edema, diabetic macula edema/non-proliferative diabetic retinopathy / proliferative diabetic retinopathy, retinal vein occlusions related macular edema, and choroidal neovascularization secondary to multiple retinal diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-VEGF drugs. In the current study, the primary aim is to aim to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 35 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients with neovascular age-related macular edema (nAMD), diabetic macula edema (DME)/non-proliferative diabetic retinopathy (NPDR)/ proliferative diabetic retinopathy (PDR), retinal vein occlusions related macular edema, and choroidal neovascular (CNV) secondary to multiple retinal diseases.
• Undergo intravitreal anti-VEGF therapy

Exclusion criteria

• unable to receive OCT examination
• Severe corneal opacity, cataract that affect OCT examination

Trial design

1,000 participants in 5 patient groups

Neovascular age-related macular edema

Description:

Patients with new-onset and recurrent Neovascular age-related macular edema.

Treatment:

Drug: Conbercept

Drug: Ranibizumab

Drug: Aflibercept

Diabetic macula edema

Description:

Patients with new-onset and recurrent diabetic macula edema

Treatment:

Drug: Conbercept

Drug: Ranibizumab

Drug: Aflibercept

Non-proliferative diabetic retinopathy/proliferative diabetic retinopathy

Description:

Patients with new-onset and recurrent non-proliferative diabetic retinopathy/proliferative diabetic retinopathy

Treatment:

Drug: Conbercept

Drug: Ranibizumab

Drug: Aflibercept

Retinal vein occlusions

Description:

Patients with new-onset and recurrent retinal vein occlusions

Treatment:

Drug: Ranibizumab

Choroidal neovascularization

Description:

Patients with new-onset and recurrent choroidal neovascularization

Treatment:

Drug: Conbercept

Drug: Ranibizumab

Drug: Aflibercept